Get access

Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)

Authors


  • Conflict of Interest: Andrew M. Blumenfeld has received grants or honoraria from Allergan, Inc., Pfizer, Zogenix, Merck, OrthoMcNeil, MAP Pharmaceuticals, Forrest, GSK, and Posen. Lisa M. Bloudek is an employee of Allergan, Inc. Werner J. Becker has served on medical advisory boards for and received speaker's honoraria from Allergan, Inc., Merck, and Johnson & Johnson; and has performed clinical trials research for Allergan, Inc., Medtronic, Merck, and AGA Medical. Dawn C. Buse has received honoraria and/or research funding from Allergan, Inc., Endo Pharmaceuticals, Merck, Inc., MAP Pharmaceuticals, NuPathe, and Novartis. Sepideh F. Varon is an employee of Allergan, Inc. Gregory A. Maglinte was an employee of Allergan, Inc. Teresa K. Wilcox is an employee of United BioSource Corporation. Ariane K. Kawata is an employee of United BioSource Corporation. Richard B. Lipton holds stock options in eNeura Therapeutics (a company without commercial products); serves as consultant, advisory board member, or has received honoraria from: Allergan, Inc., American Headache Society, Autonomic Technologies, Boston Scientific, Bristol-Myers Squibb, CogniMed, CoLucid, Eli Lilly, Endo, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, and Pfizer.
  • Financial Support: No NIH funding was provided for this manuscript or any work related to it.
  • All work performed at Allergan Inc.

Address all correspondence to A.M. Blumenfeld, The Neurology Center, 320 Santa Fe Drive, Suite 150, Encinitas, CA 92024, USA, email: blumenfeld@neurocenter.com

Abstract

Objective

Our objective was to characterize patterns of preventive medication use in persons with episodic migraine (EM) and chronic migraine (CM).

Background

Several classes of medications are used both on- and off-label for the prevention of migraine, including β-blockers (eg, propranolol, timolol), tricyclic antidepressants (eg, amitriptyline), anti-epileptic drugs (eg, topiramate, valproic acid), and neurotoxins (eg, onabotulinumtoxinA).

Methods

Preventive medication use and reasons for discontinuation were collected in an international, Web-based, cross-sectional survey of adults with migraine during 2010. Descriptive analyses were conducted on demographics and headache-related disability as measured by the Migraine Disability Assessment Scale, stratified by use of preventive medication, and EM or CM. Univariate and multivariate logistic regression models were constructed to assess predictors of preventive medication use.

Results

One thousand one hundred and sixty-five respondents completed the survey. Only 28.3% of EM and 44.8% of CM respondents were currently using preventive medication; any use of prophylaxis (prior or current) was reported by 43.4% of those with EM and 65.9% with CM. The mean number of prophylactic medications ever used was 2.92 for EM and 3.94 for CM. Antidepressants were used most frequently (EM 60.9%; CM 54.7%), followed by β-blockers (EM 35.4%; CM 36.8%) and anti-epileptics (EM 28.6%; CM 36.3%). Odds of preventive medication use were higher among CM than EM, adjusting for age, gender, race, years of daily headache, and country (odds ratio 2.72; 95% confidence interval 2.15 to 3.57). Greater headache-related disability and older age were also associated with greater odds of ever having used prophylaxis, regardless of headache frequency.

Conclusions

Less than half the persons with EM and CM were currently using preventive medication for migraine, with treatment rates being higher for CM, as expected. Those with CM tried more medications than those with EM, possibly reflecting higher levels of treatment need.

Get access to the full text of this article

Ancillary